Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma during Anti-CD20 Therapy - Nagai, Hiroyuki; Saito, Makoto; Adachi, Eisuke; Sakai-Tagawa, Yuko; Yamayoshi, Seiya; Kiso, Maki; Kawamata, Toyotaka; Koga, Michiko; Kawaoka, Yoshihiro; Tsutsumi, Takeya; Yotsuyanagi, Hiroshi (Japanese Journal of Infectious Diseases, 2022)
Keywords: Antibodies; Antibodies, Viral; Antiviral agents; BNT162 Vaccine; casirivimab and imdevimab; CD20 antigen; Chronic infection; Computed tomography; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Drug resistance; Humans; immunocompromised host; Immunocompromised hosts; Immunotherapy; Infections; Lymphoma; Lymphoma, Follicular - drug therapy; Lymphoma, Follicular - pathology; Monoclonal antibodies; mRNA; mRNA Vaccines; Mutation; Patients; Pneumonia; Polymerase chain reaction; prolonged viral shedding; Risk analysis; Risk factors; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Viral diseases; viral isolation; Viruses; COVID-19; casirivimab and imdevimab; viral isolation; immunocompromised host; prolonged viral shedding